US 11,963,946 B2
MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin, or other psychedelics
Matthias Emanuel Liechti, Oberwil (CH)
Assigned to Universitätsspital Basel, Basel (CH)
Filed by Universitätsspital Basel, Basel (CH)
Filed on Apr. 22, 2021, as Appl. No. 17/238,088.
Claims priority of provisional application 63/020,261, filed on May 5, 2020.
Prior Publication US 2021/0346341 A1, Nov. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 25/22 (2006.01); A61K 31/36 (2006.01); A61K 31/48 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/36 (2013.01) [A61K 31/48 (2013.01); A61P 25/22 (2018.01)] 4 Claims
OG exemplary drawing
 
1. A method of treating a psychiatric disorder that affects mood including the step of:
administering a synergistic amount of 3,4-methylenedioxymethamphetamine (MDMA) in combination with a synergistic amount of LSD together in a single dosage form to a human individual, wherein MDMA is administered in a dose of 20-200 mg and LSD is administered in a dose of 0.05-0.3 mg, wherein said administration enhances a mood of the patient prior to administration of the psychedelic and improves good drug effects of blissful state and feeling open and reduces bad drug effects of anxiety as measured with psychometric assessments of Subjective Effects Questionnaire (Visual Analog Scales (VAS)) and 5-Dimensional Altered States of Consciousness ((5D-ASC), and wherein the MDMA enhances a positive over negative mood effect profile of the LSD in the individual; and
treating the psychiatric disorder that affects mood chosen from the group consisting of depression and anxiety.